Newsletter | June 9, 2021

06.09.21 -- Discussions On Diversity -- How To Solve Pharma's Patient Problem

Featured Editorial
Industry Insights
Four Reasons For The Rise In Blister Packaging

Blister packaging, not long ago considered a less significant segment of the North American pharmaceutical packaging industry, is now outpacing most other industry segments. The pharmaceutical manufacturing industry has witnessed a significant increase in the number of drug approvals by the FDA over the past few years leading to several packaging innovations. Here are the factors that are driving blister to the forefront of pharmaceutical packaging, and at an even faster rate than its current growth.

Improve Training, Increase Participation, Reduce Redundancy, And Cut Costs: Why Virtual Site Training Is The New Norm

The use of virtual training through web-based meetings existed long before COVID-19, but the pandemic made web-based on-demand training the new norm. Check out this article to learn more on how virtual site training can help increase site participation, reduce redundancies, and cut costs.

Decentralized Trials: The Reality Behind The Buzzword

The concept of decentralized clinical trials is not new, but in response to COVID-19 disruptions, research operations leaders were forced in 2020 to accelerate their plans for remote and virtual trials. In response, decentralized clinical trials have become a primary innovation in the clinical operations ecosystem. But the meaning of the term “decentralized clinical trials” is not universally understood.

Preparing Monitors For Tomorrow’s Clinical Trials

CRAs have a difficult job — from the extensive travel to the tedious time spent preparing for on-site visits and completing trip reports. Approximately 25% to 30% of total clinical trial costs are attributed to site monitoring; however, this can be streamlined with a risk-based approach.

Applying The 10x Strategy To Clinical Trials: How Every New Treatment Can Move At Warp Speed

Imagine how many lives would be saved if we were able to develop treatments at warp speed instead of the years it typically takes before a medicine is approved? Learn how Elligo’s strategy can efficiently locate and enroll patients to accelerate clinical trial timelines.

Considerations For Your First Clinical Trial

For a small and emerging biopharma, moving into the clinical trial phase of development can be overwhelming, and clinical research organizations (CROs) do not typically manage the comprehensive clinical trial supply chain. Discover seven best practices to help ensure a successful trial.

The Future Of Clinical Research Technology

No human endeavor is immune to change, and that is certainly true for clinical research. John Neal, CEO of PCRS Network, spent a year talking to sponsors, management, and other various roles in clinical research in an effort to identify the factors that are shaping the future of clinical research. And while the views vary, one factor looms above all others.

Embracing Innovative Designs In Early-Phase Oncology Trials

Advancements in science and technology are driving accelerated timelines and creative pathways for oncology drug development. Oncology sponsors and regulators seek new ways to efficiently move promising therapies from the clinic to approval — embracing a streamlined path that bypasses the traditional development paradigm of standalone sequential Phase 1/2/3 trials.

Key To A Faster, More Flexible Clinical Trial Process

How a single, integrated data analytics and visualization platform, supported by an experienced partner, can help you move your investigational product to market more quickly.

The Case For Patient Diversity In Clinical Trials

Two of America’s greatest assets are its diverse demographics and its relentless pursuit of new medicines and treatments to improve patient lives worldwide. Unfortunately, it’s a widely known (but little discussed) challenge that the two do not go hand in hand. Minority participation in clinical trials is staggeringly deficient.

Thermo Fisher Scientific Pharma Services Global Network

Our objective is to help speed your molecule through early-phase trials to prepare you for commercial success. This e-book explains our comprehensive support to help streamline the end-to-end process.

How COVID-19 Has Changed The eCOA/ePRO Landscape

The COVID-19 pandemic has had a profound impact on families, communities, industries, and economies, and that impact may be felt for years. The disruption caused by it has necessitated significant changes to the way we work and live. Dorothy Brown interviews Donna Mongiello as they discuss how to adapt to crises that impact the industry and speed up the adoption of technological tools to meet current and long-term needs. Despite the pain and disruption that this pandemic has created, it has enabled an opportunity for drug developers to explore new patient-facing technologies. Watch the webinar to learn more.

Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.